The US FDA has granted approval for a label update to Eli Lilly and Company's Amyvid (florbetapir F 18 injection) for use ...

Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

June is Brain and Alzheimer’s Awareness Month — a chance to examine real-world data that links new treatments to changing clinical behavior.

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 ...

Kisunla is currently undergoing a health technology assessment. Two newly approved Alzheimer’s treatments, Kisunla (donanemab ...

A new drug for treating early-stage Alzheimer’s disease has been administered for the first time in Taiwan on an 83-year-old ...

The following six biosimilars were given a positive opinion at the June meeting: treatments for treatment of age-related macular degeneration and visual impairment: Mynzepli (aflibercept), and its ...

The new medications are currently not covered by Taiwan’s health insurance system but are available to patients who can pay ...

One of two newly approved drugs for Alzheimer’s disease has been submitted for National Health Insurance (NHI) coverage, and ...

Our federal lawmakers should substantial and sustained investments for Alzheimer’s research funding and the dementia public ...